TOFA 100 mg | 99.71%
TargetMol
TOFA
Search Results
ICA-069673 5 mg | 99.66%
TargetMol
ICA-069673 is an activator of KCNQ2/Q3 potassium channel (IC50: 0.69 μM).
More Information Supplier PageICA-069673
ICA-069673 50 mg | 99.66%
TargetMol
ICA-069673 is an activator of KCNQ2/Q3 potassium channel (IC50: 0.69 μM).
More Information Supplier PageICA-069673
ICA-069673 25 mg | 99.66%
TargetMol
ICA-069673 is an activator of KCNQ2/Q3 potassium channel (IC50: 0.69 μM).
More Information Supplier PageICA-069673
1-Deoxynojirimycin 25 mg | 99.82%
TargetMol
1-Deoxynojirimycin is a potent α-glucosidase inhibitor, suppressing postprandial blood glucose, thereby possibly preventing diabetes mellitus.
More Information Supplier Page1-Deoxynojirimycin
1-Deoxynojirimycin 10 mg | 99.82%
TargetMol
1-Deoxynojirimycin is a potent α-glucosidase inhibitor, suppressing postprandial blood glucose, thereby possibly preventing diabetes mellitus.
More Information Supplier Page1-Deoxynojirimycin
Eliglustat 5 mg | 99.71%
TargetMol
Eliglustat is an oral inhibitor of glucosylceramide synthase which is used in the therapy of type 1 Gaucher disease.
More Information Supplier PageEliglustat
Eliglustat 50 mg | 99.71%
TargetMol
Eliglustat is an oral inhibitor of glucosylceramide synthase which is used in the therapy of type 1 Gaucher disease.
More Information Supplier PageEliglustat
Eliglustat 1 mg | 99.71%
TargetMol
Eliglustat is an oral inhibitor of glucosylceramide synthase which is used in the therapy of type 1 Gaucher disease.
More Information Supplier PageEliglustat
Eliglustat 10 mg | 99.71%
TargetMol
Eliglustat is an oral inhibitor of glucosylceramide synthase which is used in the therapy of type 1 Gaucher disease.
More Information Supplier PageEliglustat